Background. Proton pump inhibitors (PPIs) are currently the most effective agents for acid-related disorders. However, studies show that 25–75% of patients receiving intravenous PPIs had no appropriate justification, indicating high rates of inappropriate prescribing.
References
[1]
Afif W, Alsulaiman R, Martel M, Barkun AN. 2007. Predictors of inappropriate utilization of intravenous proton pump inhibitors. Alimentary Pharmacology and Therapeutics 25:609-615
[2]
Alsultan MS, Mayet AY, Malhani AA, Alshaikh MK. 2010. Pattern of intravenous proton pump inhibitors use in ICU and Non-ICU setting: a prospective observational study. Saudi Journal of Gastroenterology 16:275-279
[3]
Brett S. 2005. Science review: the use of proton pump inhibitors for gastric acid suppression in critical illness. Critical Care 9:45-50
[4]
Brunner G, Luna P, Hartmann M, Wurst W. 1997. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale Journal of Biology and Medicine 69:225-231
[5]
Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, Valdovinos MA. 2008. Use and overuse of proton pump inhibitors in cirrhotic patients. Medical Science Monitor 14:CR468-CR472
[6]
Craig DGN, Thimappa R, Anand V, Sebastian S. 2010. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM 3:327-335
[7]
Forgacs I, Loganayagam A. 2008. Overprescribing proton pump inhibitors. BMJ 336:2-3
[8]
Ghassemi K, Kovacs T, Jensen D. 2009. Gastric acid inhibition in the treatment of peptic ulcer hemorrhage. Current Gastroenterology Reports 11:462-469
[9]
Gingold AR, Narasimhan G, Augello S, Clain DJ. 2004. The prevalence of proton pump inhibitor use in hospitalized patients. Practical Gastroenterology 30:24-36
[10]
Greenhalgh T, Gill P. 1997. Pressure to prescribe. BMJ 315:1482-1483
[11]
Grime J, Pollock K, Blenkinsopp A. 2001. Proton pump inhibitors: perspectives of patients and their GPs. British Journal of General Practice 51:703-711
[12]
Hayes SM, Murray S, Dupuis M, Dawes M, Hawes IA, Barkun AN. 2010. Barriers to the implementation of practice guidelines in managing patients with nonvariceal upper gastrointestinal bleeding: a qualitative approach. Canadian Journal of Gastroenterology 24:289-296
[13]
Hoover J, Schumaker A, Franklin K. 2009. Use of intravenous proton-pump inhibitors in a teaching hospital practice. Digestive Diseases and Sciences 54:1947-1952
[14]
Leontiadis GI, Sharma VK, Howden CW. 2005. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 330-568
[15]
MacLaren R, Obristsch MD, Sherman DS, Jung R, Fish DN. 2006. Assessing adherence to an intravenous pantoprazole guideline. Journal of Pharmacy Technology 22:15-21
[16]
Metz DC. 2000. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion 62:73-81
[17]
Nasser SC, Nassif JG, Dimassi HI. 2010. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World Journal of Gastroenterology 16:982-986
[18]
Naunton M, Peterson GM, Bleasel MD. 2000. Overuse of proton pump inhibitors. Journal of Clinical Pharmacy and Therapeutics 25:333-340
[19]
Sebastian SS, Kernan N, Qasim A, O’Morain CA, Buckley M. 2003. Appropriateness of gastric antisecretory therapy in hospital practice. Irish Journal of Medical Science 172:115-117
[20]
Slattery E, Theyventhiran R, Cullen G, Kennedy F, Ridge C, Nolan K, Kidney R, O’Donoghue DP, Mulcahy HE. 2007. Intravenous proton pump inhibitor use in hospital practice. European Journal of Gastroenterology & Hepatology 19:461-464
[21]
Vanderhoff BT, Tahboub RM. 2002. Proton pump inhibitors: an update. American Family Physician 66(2):273-280
